Talk:David Edwards (engineer)

Central(e)

At some point I noticed that Centrale Paris (redirect to École Centrale Paris) was changed to Central Paris, by someone who presumably thought it was a spelling error. It has been restored, but why not make it École Centrale Paris to discourage that from happening again? … I'll be Bold. —Tamfang (talk) 05:20, 31 December 2019 (UTC)

Updates requested on David Edwards's page - for discussion to ensure respecting Wikipedia's guidelines. Work is cited in references

To whom it may concern, I would like to submit the following changes / edits on this page to reflect more accurate information, while remaining neutral and avoiding any wikipedia copyright issues. please take the edits you see fit.

- David Edwards (engineer). Although this is true, he is more known for his inventions and his writing rather than his education or him being an engineer. David Edwards stepped down as professor of Harvard University in June (see Harvard University website). He now leads a start-up Sensory Cloud, which he founded as well as the World Frontiers Forum. Proposed changes below

David Edwards recently left the School of Engineering and Applied Sciences at Harvard University to lead his startup company Sensory Cloud.[1] He is an inventor, a writer of fiction and nonfiction, and the founder of Le Laboratoire,[2] an experimental art and design center that led to the World Frontiers Forum.[3]

Research and entrepreneurship proposed changes below

Edwards' scientific work concerns the research and development of advanced new drug delivery platforms, ranging from treating infectious diseases in the developing world to personal olfaction. He has published many scientific papers and two textbooks in the areas of applied mathematics and advanced transport analysis. He is a founder of Advanced Inhalation Research, or AIR, sold to Alkermes, Inc. and leading to the FDA approved product inbrijia,[4] inhaled L-Dopa for Parkinson’s, of Pulmatrix, of Incredible Foods, and of Medicine in Need, an international non-governmental organization aimed at developing new drugs and vaccines for diseases of poverty, such as tuberculosis.[5][6]. His company Sensory Cloud launched a first product on the market in 2019, called Nimbus.

Art and fiction proposed changes below

Edwards' artistic work includes his books Artscience: Creativity in the Post-Google Generation (Harvard Press 2008), The Lab (Harvard University Press 2010, in French, Manifeste du Laboratoire, Odile Jacob), and Creating Things That Matter (Holt 2018), winner of a 2018 Nautilus Award (for creative process).[9] Edwards’ views on aesthetics are also expressed in the graphic novels that accompanied the first years of Le Laboratoire (Niche 2007 École de Beaux Arts, in French, Harvard University Press, in English, and Whif 2008, Harvard University Press), fictional interpretations of the playful zones where artists and scientists find common expression, drawn explicitly from his artistic collaborations with artists, designers, and chefs, which he has continued in recent years with the winners of the Frontier Art Prize, founded in 2016 with Bridgitt Evans, President of VIA Art Fund, including — Doug Aitken (2017), Tavares Strachan (2018) and Agnieszka Kurant (2019).[10] His novel Niche (Editions Le Laboratoire and École nationale supérieure des Beaux-Arts, 2007), on which he has collaborated with the American novelist Jay Cantor and the photographer Daniel Faust, explores the conceptual bases of Le Laboratoire's creation.

Academic biography proposed changes below Edwards studied chemical engineering at Michigan Technological University as an undergraduate, receiving a B.S. in 1983, and going on to a Ph.D. in 1987 in the same subject from the Illinois Institute of Technology. After a brief postdoctorate and lecturership at the Technion in Israel, he taught for four years at the Massachusetts Institute of Technology and for three more at Pennsylvania State University before leaving academia in 1998 to found Advanced Inhalation Research. In 2002, he was hired as the McKay Professor of the Practice at Harvard.[7] He left Harvard in spring 2019 to lead his startup company Sensory Cloud.

Awards and honors proposed changes below

Edwards was elected to the National Academy of Engineering in 2001.[8] He has also been honored three times by the American Pharmaceutical Association with their Ebert Prize, and has won the Jerusalem Fund's Theodor Herzl Award, the European Aerosol Association's Smoluchowski Award, and the American Institute of Chemical Engineers' Professional Progress Award.[1] In 2007, he was awarded the Melvin Calvin Medal of Distinction by his alma mater Michigan Tech, its highest honor.[9]. Edwards was also elected in 2008 to the French National Academy of Engineering (l’académie des technologies) and was made a chevalier of arts and letters by the French Ministry of Culture also in 2008. Edwards was recently elected to the US National Academy of Inventors.

References proposed changes below

1. Coming Soon to Bar Near You: A Flavor Hack for Food and Drink.Forbes. July 19, 2019. 2. Le Laboratoire. Time Out. 19 Octobre, 2011; James Nachtway expose au Laboratoire. Paris Match. 2 Février 2008; Le homard m’a tue. Télérama. 23 mai 2008; WikiCells lance un concept d’emballage comestible. Les Échos. 15 Juin 2012; Il a imagine l’emballage 100% comestible. Paris Match 14 octobre 2013; Starck invente le spray WAHH qui rend ivre. L’Express; Matters of Taste. New York Times. February 26, 2014. 3. Asking After The Future at the World Frontiers Forum. Fast Company. October 12, 2017. 4. Inbrijia Approved in US to Treat Off-Periods in Parkinson’s Patients on Carbidopa/Levadopa. Parkinson’s News Today. January 10, 2019. 5. ^ Chutzpah Science, Forbes magazine, May 25, 2005. 6. ^ Nose Spray May Slow Spread of Germs, Fox News, November 30, 2004. 7. ^ Biography from Edwards' web site. 8. ^ NAE citation: "For transfer of scientific principles of engineering to industry, including invention and commercial development of a novel, generic aerosol drug-delivery system.". 9. ^ Harvard's David A. Edwards, Ph.D., honored at Commencement, Department of Chemical Engineering, Michigan Technological University 10. Agnieszka Kurant wins $100,000 Frontier Art Prize. ArtForum. October 25, 2019.

Mxaviere (talk) 19:21, 2 January 2020 (UTC)

Mxaviere thank you for using the talk page. Unfortunately you will need to slow down and be a lot clearer than the above. The simplest thing to do is take things one at a time, and request a change in the style of "please change x to y" and then provide a link to a reference specifically for y. You can use the Template:Request edit if you like. Please also note that a number of the current links to references in the article are to error pages. If you can provide a source that other editors can check, that will help verify the content you are proposing, which is a core principle of wikipedia. thank you. Melcous (talk) 01:44, 3 January 2020 (UTC)

Request Edit Nov 5 2020

I work for David A. Edwards, the biomedical engineer and therefore have conflict of interest. I am submitting the following proposed changes for independent editors to evaluate, in accordance with the directions at Wikipedia's Contact Us [1] page for the subjects of articles or their representatives in the event "an article about you or your organization is incomplete, inaccurate, or biased."

1. Please add an infobox:(the inbox is published on the far right with a photo)

David A. Edwards
Born	David A. Edwards (1961-04-06)April 6, 1961 Ann Arbor, Michigan, U.S.
Alma mater	Michigan Technological University, B.S. Illinois Institute of Technology, PhD
Scientific career
Fields	Biomedical engineering
Institutions	Harvard University
Website	davidideas.com

Rationale: Reformatting to adhere to Good Article standards for a biography.

2. Please replace the first sentence: David A. Edwards is a Professor of the Practice of Biomedical Engineering at Harvard University.

WITH THE FOLLOWING TWO PARAGRAPHS.

David A. Edwards, (born April 6, 1961), is an American biomedical engineer, inventor, author and CEO of the company Sensory Cloud. He was named the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University.

Edwards is known for designing inhalable medicines, vaccines and victuals. In 2020 Sensory Cloud released a product designed to clean respiratory droplets from the airways, of the kind that potentially carry viruses like Severe acute respiratory syndrome coronavirus 2 that cause COVID-19.

Rationale: Adds critical biographical information, supported by reliable sources CBS Sunday Morning, the Boston Globe and Fast Company.

3. Please rename the section “Education” to “Early Life and Education”

Rationale: Reformatting to adhere to Good Article standards for a biography, which include details of the subject’s early life foundation and education.

4. In the new “Early Life and Education” section, please replace the paragraph that reads: “ Edwards studied chemical engineering at Michigan Technological University as an undergraduate, receiving a B.S. in 1983, and going on to a Ph.D. in 1987 in the same subject from the Illinois Institute of Technology. After a brief post doctorate and lectureship at the Technion in Israel, he taught for four years at the Massachusetts Institute of Technology and for three more at Pennsylvania State University before leaving academia in 1998. In 2002, he was hired as the McKay Professor of the Practice at Harvard.”

WITH THE FOLLOWING TWO PARAGRAPHS:

Edwards was born in Ann Arbor, Michigan.

Edwards studied chemical engineering, receiving a B.S. from Michigan Technological University in the field in 1983, and a Ph.D. in 1987 from the Illinois Institute of Technology.

Rationale: Adds reliable sources. Removes info that should be in the new “Career” section.

5. Please rename the section “Research” to “Career”

Rationale: Section title “Career” better reflects Edwards’ academic and entrepreneurial career, both of which are dependent upon his research.

6. In the new “Career Section”, please replace the paragraph that reads: “Edwards' scientific work concerns the research and development of drug delivery platforms for treating infectious diseases in the developing world. He is a founder of Advanced Inhalation Research, or AIR, now part of Alkermes, Inc., of Pulmatrix, and of Medicine in Need, an international non-governmental organization aimed at developing new drugs and vaccines for diseases of poverty, such as tuberculosis.”

WITH:

Between 1987 and 1995, Edwards held a postdoctoral and lectureship at the Technion in Israel and the Massachusetts Institute of Technology. While at MIT, Robert Langer, a professor at MIT, encouraged Edwards to use his math skills to develop an efficient way for inhalers to deliver medicine to the lungs. Edwards joined the Pennsylvania State University faculty as an Associate Professor of Chemical Engineering in 1995, where he continued to research ways to make medicine inhalable. In 1997, Science published his study on a new type of inhalable aerosol that efficiently delivered drugs to the lungs. Edwards left academia in 1998 when he and Langer founded Advanced Inhalation Research (AIR); the startup was purchased a year later by Alkermes for $114 million. He returned to academia in 2002, joining the Harvard faculty.

Rationale: Adds critical information about the beginning of Edwards’ career and reliable supporting sources.

7. In the new “Career” section, please add the following as the new third, fourth and fifth paragraphs:

Edwards founded Medicine in Need in 2003, a international non-governmental organization aimed at developing new drugs and vaccines for diseases such as tuberculosis.

His company Pulmatrix, a pharmaceutical company that creates drugs to combat inhaled infectious diseases, launched in 2003.

In 2007, Edwards opened Le Laboratoire, a not-for-profit art, science and design center. Edwards’ Harvard lab developed a dry-powder aerosol tuberculosis vaccine that was found in 2008 to be more effective than a traditional shot in animal trials.

Rationale: Adds highly notable milestones in Edwards’ career, along with reliable sourcing.

8. In the new “Career” section, please add the following as the new seventh and eighth paragraph:

In 2014 he opened Cafe ArtScience, a restaurant, bar, gallery, lab and store in Cambridge that featured inhalable drinks and food with edible skin. The same year, Edwards and a former student launched the oPhone, a device where users could send scented messages via mobile platforms to recipients. Edwards founded Incredible Foods, a company that uses technology to package food in allergen-free edible skins, in 2015.

Cafe ArtScience closed in 2019, but was followed by the opening of the restaurant Senses in summer of 2020.

Rationale: Includes relevant details about the continued expansion and use of Edwards’ inhalable technology, and supporting reliable news sources.

10. In the new “Career” section, please add the following as the new ninth paragraph:

In 2020, Edwards’ company Sensory Cloud released the Fast Emergency Nasal Defense (FEND) Mist Maker, a product designed to reduce infected air droplets from viruses like SARS-CoV-2, a strain of coronavirus known to cause COVID-19. A study of 10 participants found using FEND reduced potentially infected aerosols by up to 99 percent for six hours.

Rationale: Updates the section with details of Edwards’ application of inhalable technology to the COVID-19 epidemic. Provides supporting mainstream sources.

11. After the “Career” section, please add a new section “Awards and recognition“ and add the following text:

In 2001, at age 39, Edwards became the youngest person elected to the National Academy of Engineering. He was elected to the National Academy of Inventors in 2013.

Rationale: Adding this as a section follows Good Article practice (for example, Pin Malakul. The proposed section will include highly prestigious awards and recognition from notable organizations with Wikipedia pages. Edwards’ election to both organizations is an important milestone in his career. Adds supporting reliable sources.

12. Please add a new section “Personal Life“ and the following text:

Edwards, his wife and two children live between Boston and Paris.

Rationale: Personal life section is standard for Wikipedia biographies.

13. To the section “Publications”, please add the following to the top of the list, ensuring chronological order:

• Edwards, David; Cantor, Jay (1 March 2008). Niche. Harvard University Press. ISBN 9780674027909.
• Edwards, David (31 March 2009). Whiff. Harvard University Press. ISBN 9780674032866.
• Edwards, David (30 March 2010). ArtScience: Creativity in the Post-Google Era. Harvard University Press. ISBN 978-0674034648.

Rationale: Updates current Publications section with two more of Edwards’ books.

Thanks for your consideration! PC7956 (talk) 21:01, 5 November 2020 (UTC)

Starting from bottom up: 13) two books added to list; 12) Personal life section added; 11) NOT DONE as membership in those Academies number in many hundreds; 10) NOT DONE, as too preliminary to be meaningful or mentionable; 9) there is no #9; 8) NOT DONE, as in my opinion too trivial to be career milestones; 4) done. I did not look at the others. David notMD (talk) 19:42, 9 November 2020 (UTC)

References

Request Edits December 15, 2020

I work for David A. Edwards, the biomedical engineer and therefore have conflict of interest. I am submitting the following proposed changes for independent editors to evaluate, in accordance with the directions at Wikipedia's Contact Us [2] page for the subjects of articles. 1. Please add an infobox. I have done all the coding, which is flush right on this page.

David A. Edwards
Born	David A. Edwards (1961-04-06)April 6, 1961 Ann Arbor, Michigan, U.S.
Alma mater	Michigan Technological University, B.S. Illinois Institute of Technology, PhD
Scientific career
Fields	Biomedical engineering
Institutions	Harvard University
Website	davidideas.com

Rationale: Reformatting to adhere to Good Article standards for a biography.

2. Please replace the first sentence: David A. Edwards is a Professor of the Practice of Biomedical Engineering at Harvard University.

WITH THE FOLLOWING TWO PARAGRAPHS.

David A. Edwards, (born April 6, 1961), is an American biomedical engineer, inventor, author and CEO of the company Sensory Cloud. He was named the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University.

Edwards is known for designing inhalable medicines, vaccines and victuals. In 2020 Sensory Cloud released a product designed to reduce infected air droplets from viruses like Severe acute respiratory syndrome coronavirus 2 that cause COVID-19.

Rationale: Adds critical biographical information, supported by reliable sources CBS Sunday Morning, the Boston Globe and Fast Company.

3. Please rename the section “Research” to “Career”

Rationale: Section title “Career” better reflects Edwards’ academic and entrepreneurial career, both of which are dependent upon his research.

4. In the new “Career Section”, please replace the paragraph that reads: “Edwards' scientific work concerns the research and development of drug delivery platforms for treating infectious diseases in the developing world. He is a founder of Advanced Inhalation Research, or AIR, now part of Alkermes, Inc., of Pulmatrix, and of Medicine in Need, an international non-governmental organization aimed at developing new drugs and vaccines for diseases of poverty, such as tuberculosis.”

WITH:

Between 1987 and 1995, Edwards held a postdoctoral and lectureship at the Technion in Israel and the Massachusetts Institute of Technology. While at MIT, Robert Langer, a professor at MIT, encouraged Edwards to use his math skills to develop an efficient way for inhalers to deliver medicine to the lungs. Edwards joined the Pennsylvania State University faculty as an Associate Professor of Chemical Engineering in 1995, where he continued to research ways to make medicine inhalable. In 1997, Science published his study on a new type of inhalable aerosol that efficiently delivered drugs to the lungs. Edwards left academia in 1998 when he and Langer founded Advanced Inhalation Research (AIR); the startup was purchased a year later by Alkermes for $114 million. He returned to academia in 2002, joining the Harvard faculty.

Rationale: Adds critical information about the beginning of Edwards’ career and reliable supporting sources.

5. In the new “Career” section, please add the following as the new third, fourth and fifth paragraphs:

Edwards founded Medicine in Need in 2003, a international non-governmental organization aimed at developing new drugs and vaccines for diseases such as tuberculosis.

His company Pulmatrix, a pharmaceutical company that creates drugs to combat inhaled infectious diseases, launched in 2003.

In 2007, Edwards opened Le Laboratoire, a not-for-profit art, science and design center. Edwards’ Harvard lab developed a dry-powder aerosol tuberculosis vaccine that was found in 2008 to be more effective than a traditional shot in animal trials.

Rationale: Adds highly notable milestones in Edwards’ career, along with reliable sourcing.

6. Please remove the flag on top of the article. Everything in the article already has a reliable secondary source with the exception of his out-of-date title -- and this has been updated and sourced in the first Request Edit.

7. In the new “Career” section, please add the following as the new ninth paragraph:

In 2020, Edwards’ company Sensory Cloud released the Fast Emergency Nasal Defense (FEND) Mist Maker, a product designed to reduce infected air droplets from viruses like SARS-CoV-2, a strain of coronavirus known to cause COVID-19. A study of 10 participants found using FEND reduced potentially infected aerosols by up to 99 percent for six hours. In a peer-reviewed study in PNAS published in February 2021, Edwards and his colleagues found that “exhaled aerosol increases with COVID-19 infection, age, and obesity.” “These findings suggest that quantitative assessment and control of exhaled aerosol may be critical to slowing the airborne spread of COVID-19 in the absence of a widely available vaccine.” the study concludes.

Rationale: Covered in both the Boston Globe and Fast Company, two very high quality sources. Plus, nsw published article in a highly-regarded peer reviewed journal shows prevalence of exhaled aerosol in certain populations.

Thank you. PC7956 (talk) 19:35, 12 January 2021 (UTC)

References

I removed the banner but added more cite needed tags. The medical claims in items 2, 5 and 7 need WP:MEDRS sources. The Harvard Gazette, Boston Globe and Fast Company do not meet that standard, so items 2, 5 and 7 are  Not done. Additionally, the wording of those claims appears very promotional to me. I haven't carefully evaluated items 1, 3, and 4. —David Eppstein (talk) 21:41, 18 March 2021 (UTC)

I have added items 1, 3 and 4; but removed "math skills" as it reads overly promotional. Best, 15 (talk) 18:41, 17 April 2021 (UTC)

Here is additional information requested by User: David Eppstein that should be sufficient to answer the "Not Done" objections for 2, 5, 7

1. Re: #2 a) What follows is proposed rewrite of the first part of #2. What’s important is that he is now working as the founder of a company called Sensory Cloud, not as a Harvard professor. So the current lead is inaccurate. It needs to cover both to be accurate. Here is a shorter version, which I hope you will find less promotional as well:

David A. Edwards, (born April 6, 1961), is an American biomedical engineer, and the founder of Sensory Cloud. He was the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University.

b) Re: #2, second part of the request, please keep in mind that this is a biographical article about a person who is both a company founder and a promninent academic researcher. So, a secondary press source about his business career that does not make medical claims, should be more than adequate under WP:RS. We need to establish his career details. Nonetheless, I have rewritten the second part of #2 so it sounds more neutral and I have added academic citations from peer-reviewed journals that his career involves designing inhalable medicines and vaccines, sufficient under WP:MEDRS. The victuals are a non-medical food items by definition so don’t require a medical source. I chose two peer-reviewed articles from among dozens. At the bottom of this request proposed a list of many more journal articles to the Selected Publications section, which right now only covers his books. As the lead summarizes the body of the text, the full list of Selected Publications should also be considered as supporting anything written in the lead.

Edwards designs inhalable medicines, vaccines and victuals.

2. Re: #5, none of these statements make medical claims except for the last sentence. So these should have all been approved or rejected based on WP:RS, not [[WP:MEDRS]. For the last sentence, I have added the appropriate peer-reviewed journal.

Edwards’ Harvard lab developed a dry-powder aerosol tuberculosis vaccine that was found in 2008 to be more effective than a traditional shot in animal trials.

As requested by User:15

3. Re: #7. The first sentence is a description of the business without a medical claim. This is what is going on in his career covered in-depth by the mainstream media. It is not promotional to state what it is he is doing with his professional life in a neutral tone. That said, I took out the name of the product in case that was triggering some concern. There has been related research showing efficacy. I have added the related journal article citation to the second sentence. The third sentence already contains a journal article citation.

In 2020, Edwards’ company Sensory Cloud released a product designed to reduce infected air droplets from viruses like SARS-CoV-2, a strain of coronavirus known to cause COVID-19. A study of 10 participants found using the product reduced potentially infected aerosols by up to 99 percent for six hours. In a peer-reviewed study in PNAS published in February 2021, Edwards and his colleagues found that “exhaled aerosol increases with COVID-19 infection, age, and obesity.” “These findings suggest that quantitative assessment and control of exhaled aerosol may be critical to slowing the airborne spread of COVID-19 in the absence of a widely available vaccine.” the study concludes.

4. To satisfy the request foe more peer-reviewed articles, please add the following peer-reviewed publications to the end of the section “Publications”:

• Edwards, D.A. (April 1994). "The macrotransport theory of nondepositing particles in the lung by convective dispersion". Journal of Aerosol Science. 25 (3): 533–565. Retrieved 17 April 2021.
• Edwards, D.A. (March 1995). "The macrotransport theory of lung dispersion: Aerosol deposition phenomena". Journal of Aerosol Science. 26 (2): 293–317. Retrieved 17 April 2021.
• Li, W. -I; Perzl, M.P.; Ferron, G.A.; Batycky, R.; Heyder, J.; Edwards, D.A. (September 1998). "The macrotransport properties of aerosol particles in the human oral-pharyngeal region". Journal of Aerosol Science. 29 (8): 995–1010. Retrieved 17 April 2021.
• Edwards, D.A.; Chen, D.; Wang, J.; Ben-Jebria, A. (1998). "Controlled release inhalation aerosols". Resp. Drug Delivery VI: 187–192.
• Wang, J.; Ben-Jebria, A.; Edwards, D.A. (1999). "Inhalation of estradiol for sustained systemic delivery". Journal of Aerosol Medicine. 12: 27–36.
• Tsapis, N.; Bennett, D.; Jackson, B.; Weitz, D.A.; Edwards, D.A. (September 2002). "Large porous carriers of nanoparticles for drug delivery". Proceedings of the National Academy of Sciences. 99: 12001–12005. Retrieved 17 April 2021.
• Wong, Y-L.; Sampson, S.; Germishuizen, W.; Goonesekera, S.; Caponetti, G.; Sadoff, J.; Bloom, B.R.; Edwards, D.A. (February 2007). "Drying a tuberculosis vaccine without freezing". Proceedings of the National Academy of Sciences. 104: 2591–2505. Retrieved 17 April 2021.

Thank you for your careful consideration.PC7956 (talk) 21:50, 19 April 2021

Hi PC7956. I'm happy with both rewritten parts of #2

RE #5: According to the sources, Medicine in Need does not develop treatments against tuberculosis but Pulmatrix does. The wording should be more precise. I don't believe the study can be used, as it would need a review-type study to confirm the efficacy of the spray. Perhaps it is possible with attribution, e.g., "A study found that...", but I am not an expert on WP:MEDRS, so it would be best to leave that out unless someone else more knowledgeable than me endorses its inclusion.

RE #7: This is also a medical claim. Perhaps it would be good to ask at an appropriate WikiProject such as Wikipedia:WikiProject_Medicine.

You can go ahead with adding the articles to the publications section, good job putting them into the right format.

Best, 15 (talk) 16:13, 11 May 2021 (UTC)::As requested by User:15, here is a revision of Request # 5 based on their guidance. #5 is from the original group of requests in this Talk section, above, regarding David Edwards, the former Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University. #7 is also from the original group and needs to be reviewed.

5. In the new “Career” section, please delete the following paragraph number two:

‘Edwards' scientific work in biomedical engineering concerns the research and development of drug delivery platforms for treating infectious diseases in the developing world. He was a founder of Advanced Inhalation Research, now part of Alkermes, Inc., of Pulmatrix, and of Medicine in Need, an international non-governmental organization aimed at developing new drugs and vaccines for diseases of poverty, such as tuberculosis.

And ADD the following as the new second, third and fourth paragraphs:

Edwards founded Medicine in Need in 2003, a international non-governmental organization aimed at developing new delivery methods for drugs and vaccines for diseases such as tuberculosis.

His pharmaceutical company, Pulmatrix, which creates drugs intended to treat inhaled infectious diseases, launched in 2003.

In 2014, Edwards opened Le Laboratoire, a not-for-profit art, science and design center.

Edwards’ Harvard lab developed a dry-powder aerosol tuberculosis vaccine that was found in 2008 to be more effective than a traditional shot in animal trials.

Rationale: The reviewing editor asked for the wording to be more precise. The revised text limits Medicine in Need’s actions to what it aims to do (developing delivery methods). The second paragraph about Pulmatrix also limits its actions to what it does (create inhalable drugs). The third paragraph uses a peer-reviewed journal to support the claim that the aerosol TB vaccine was developed and effective. Adds highly notable milestones in Edwards’ career, along with reliable sourcing.

7. The reviewing editor asked for someone with a medical background to review Request #7, from above. The editor had no comments about the request itself.

Thanks for your attention to this.PC7956 (talk) 12:08, 10 June 2021 (UTC)

References

Status this request

David Eppstein, 15, I'm working on reducing the backlog over at CAT:EDITREQ. I was wondering if you had come to an agreement with the COI editor about how to proceed and, accordingly, if we could close this request. Thanks. JBchrch talk 12:34, 30 June 2021 (UTC)

I think it can be closed as partially done. And that the COI editor should be advised to limit their requested changes to single items and not wholesale rewrites of the article. —David Eppstein (talk) 15:47, 30 June 2021 (UTC)

Closed as  Partly done. JBchrch talk 20:44, 30 June 2021 (UTC)

@JBchrch: I think this should be left open for the time being, unless you suggest repost in another manner. DavidEpstein deferred judgment on two requests immediately above (#2 and #3) because he said someone with medical knowledge should respond since he believes they involve medical claims and he is not qualified to answer these. So, as he recommended, I left a notice on Wikipedia:WikiProject Medicine I also notified WP: WikiProject Pharmacology, WP: WikiProject Biography/Science and academia. No one has responded here yet. A full Harvard BioMedical Engineering professor’s development of an aerosol vaccine for tuberculosis and an aerosol product designed to reduce infected air droplets from viruses like SARS-CoV-2 is not trivial biographical material. It’s his current life’s work. PC7956 (talk) 21:09, 30 June 2021 (UTC)

@PC7956: I see no policy-based reason that would allow me to reject your request. However, from a practical perspective, it looks to me like this edit request has more or less run its course. Considering that it is pretty long and technical, and the high standards that are applied in this area of the project, I cannot guarantee that you will find competent editors willing to take a look in the near future. What I would advise, though, is for you to open a new request on this talk page: the current one, with the interspersed answers, is not really readable for a new editor taking a look. I also advise that you take David Eppstein's advice into consideration and shorten your request to a more workable length. Thanks. JBchrch talk 10:05, 1 July 2021 (UTC)

Career Section Updates

I work for David Edwards, the founder of Sensory Cloud, formerly the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University. I have suggested updates that I think will substantially improve the overall quality and completeness of this article.

In the Career section, there is nothing about the company Edwards’ founded and is now working at -- Sensory Cloud. Edwards work at Sensory Cloud has been covered in the mainstream press (Time, Fast Company, TechCrunch, etc.). The Career section also does not include his most recent published, peer-reviewed research, even though it is widely cited and on important topics. One was published in Proceedings of the National Academy of Sciences, one of the highest impact factor academic journals. For the academic articles, I’ve, as a secondary source for each, I’ve included another journal article that discusses the findings of the primary article. The new paragraph would go at the end of the Career section:

In 2020, Edwards’ founded the company Sensory Cloud. Sensory Cloud released a nasal inhalable product intended to reduce infected air droplets from viruses like SARS-CoV-2, a strain of coronavirus known to cause COVID-19. A study of 10 participants found using the product reduced potentially infected aerosols by up to 99 percent for six hours.

In a February 2021 study in the Proceedings of the National Academy of Sciences of the United States of America, Edwards and his colleagues found that “exhaled aerosol increases with COVID-19 infection, age, and obesity.” “These findings suggest that quantitative assessment and control of exhaled aerosol may be critical to slowing the airborne spread of COVID-19 in the absence of a widely available vaccine.” the study concludes.

---

Thanks. PC7956 (talk) 16:52, 18 September 2021 (UTC)

 Partly done: Hi. I've partially implemented your requests. I don't agree 10 cases merits inclusion. PK650 (talk) 22:04, 10 October 2021 (UTC)

References